文献速递骨软组织肉瘤与黑色素瘤

晚期黑色素瘤长期缓解后停用BRAF/MEK抑制剂的临床结局

Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma.
PubMed 文献 · Eur J Cancer · 2025-12-24

该回顾性全国队列研究基于丹麦转移性黑色素瘤数据库,纳入2014至2022年接受BRAFi/MEKi治疗≥2年的患者,分析无进展停药后的结局。37例停药者中位总生存125个月,停药后中位无进展生存14个月,65%进展且多在12个月内,再诱导治疗应答率79%。

要点

  • 长期BRAFi/MEKi治疗后无进展停药,部分患者可获得长期生存。
  • 停药后进展多发生在第一年内,需密切随访。
  • 进展后BRAFi/MEKi再诱导治疗应答率高,中位PFS 25个月。

核心结论

  • 在长期接受BRAFi/MEKi治疗的黑色素瘤真实世界队列中,无进展停药后相当比例患者成为长期生存者。
  • 停药后进展通常发生在第一年内,BRAFi/MEKi再诱导治疗高度有效。
  • 对选定患者,停药可能是可行策略,但需密切随访并在进展时及时重新开始治疗。

研究设计与样本

  • 回顾性全国队列研究,使用丹麦转移性黑色素瘤数据库(DAMMED)。
  • 纳入2014至2022年接受BRAFi/MEKi治疗≥2年的转移性黑色素瘤患者。
  • 采用Kaplan-Meier分析和log-rank检验评估生存结局。

主要发现

  • 1367例患者开始BRAFi/MEKi治疗,97例接受治疗≥2年,37例在治疗开始后2至3.5年间无疾病进展停药。
  • 停药患者中位总生存为125个月,停药后中位无进展生存为14个月。
  • 停药后中位随访49个月,37例中24例(65%)进展,其中67%在12个月内进展。
  • 进展患者中19例接受BRAFi/MEKi再诱导,应答率79%,再诱导后中位无进展生存25个月(中位随访29.4个月)。

临床怎么用

  • 对长期BRAFi/MEKi治疗缓解的选定患者,可考虑无进展停药。
  • 停药后需密切随访,尤其第一年内,以便进展时及时再诱导治疗。
  • 进展后BRAFi/MEKi再诱导是有效策略。

局限性

  • 回顾性研究设计。
  • 停药患者样本量较小(37例)。
  • 预测持续肿瘤控制的临床或分子特征尚待明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: BRAF and MEK inhibitors (BRAFi/MEKi) induce high response rates and rapid tumor regression in BRAF-mutated metastatic melanoma. While responses last around 12 months, ≈ 24 % of patients in clinical trials achieve progression-free survival (PFS) beyond 3 years. The impact of discontinuing therapy after long-lasting responses remains incompletely characterized. METHODS: We conducted a retrospective nationwide cohort study using the Danish Metastatic Melanoma Database (DAMMED), to include patients with metastatic melanoma treated with BRAFi/MEKi for ≥ 2 years from 2014 to 2022. Survival outcomes were assessed using Kaplan-Meier analyses and the log-rank test. RESULTS: 1367 patients initiated treatment with BRAFi/MEKi, 97 received therapy ≥ 2 years, and 37 patients discontinued treatment in the absence of disease progression between 2 and 3.5 years from treatment initiation. Among patients who discontinued, median overall survival was 125 months and median PFS post-discontinuation 14 months. After median follow-up of 49 months post-discontinuation, 24 of 37 patients (65 %) progressed, with 67 % who progressed within 12 months. Of those who progressed, 19 were reinduced with BRAFi/MEKi, achieving a 79 % response rate; mPFS post-reinduction was 25 months (median follow-up 29.4 months). CONCLUSION: In this nationwide real-world cohort of patients with melanoma receiving prolonged BRAFi/MEKi treatment, a notable proportion of patients who discontinued treatment without progression became long-term survivors. Progression after discontinuation typically occurred within the first year, with BRAFi/MEKi-reinduction being highly effective. Treatment discontinuation could be a viable strategy for selected patients, provided close follow-up and prompt reinitiation upon progression. Identifying clinical or molecular features predictive of sustained tumor control remains essential.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Døssing RH, Hesselberg E, Clausen AB, et al. Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma. Eur J Cancer. 2025. PMID: 41456361. doi:10.1016/j.ejca.2025.116200

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。